Selective androgen receptor degrader (SARD) to overcome antiandrogen resistance in castration-resistant prostate cancer
eLife · 19.01.2023 · 12
DOI: 10.7554/elife.70700 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, online erschienen am 19.01.2023. Verfasst von Meng Wu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, Beijing, China. Hauptthemen laut MEDLINE: Receptors, Androgen, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, China Postdoctoral Science Foundation.
Abstract (Originalsprache)
In patients with castration-resistant prostate cancer (CRPC), clinical resistances such as androgen receptor (AR) mutation, AR overexpression, and AR splice variants (ARVs) limit the effectiveness of second-generation antiandrogens (SGAs). Several strategies have been implemented to develop novel antiandrogens to circumvent the occurring resistance. Here, we found and identified a bifunctional small molecule Z15, which is both an effective AR antagonist and a selective AR degrader. Z15 could directly interact with the ligand-binding domain (LBD) and activation function-1 region of AR, and promote AR degradation through the proteasome pathway. In vitro and in vivo studies showed that Z15 efficiently suppressed AR, AR mutants and ARVs transcription activity, downregulated mRNA and protein levels of AR downstream target genes, thereby overcoming AR LBD mutations, AR amplification, and ARVs-induced SGAs resistance in CRPC. In conclusion, our data illustrate the synergistic importance of AR antagonism and degradation in advanced prostate cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, Beijing, China.
- Department of Urology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
- Department of Medical Research Center, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
- Key Laboratory of the Ministry of Education for Advanced Catalysis Materials, Department of Chemistry, Zhejiang Normal University, Jinhua, China.
ORCID-Profile: Meng Wu, Rongyu Zhang, Jinming Zhou
Förderung
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
Zitieren
APA
Wu, M., Zhang, R., Zhang, Z., Zhang, N., Li, C., Xie, Y., Xia, H., Huang, F., Zhang, R., Liu, M., Li, X., Cen, S., & Zhou, J. (2023). Selective androgen receptor degrader (SARD) to overcome antiandrogen resistance in castration-resistant prostate cancer. eLife, 12. https://doi.org/10.7554/elife.70700
Vancouver
Wu M, Zhang R, Zhang Z, Zhang N, Li C, Xie Y, et al. Selective androgen receptor degrader (SARD) to overcome antiandrogen resistance in castration-resistant prostate cancer. eLife. 2023;12. doi:10.7554/elife.70700
BibTeX
@article{Wu2023,
author = {Wu, Meng and Zhang, Rongyu and Zhang, Zixiong and Zhang, Ning and Li, Chenfan and Xie, Yongli and Xia, Haoran and Huang, Fangjiao and Zhang, Ruoying and Liu, Ming and Li, Xiaoyu and Cen, Shan and Zhou, Jinming},
title = {Selective androgen receptor degrader (SARD) to overcome antiandrogen resistance in castration-resistant prostate cancer},
journal = {eLife},
year = {2023},
volume = {12},
doi = {10.7554/elife.70700}
}
EUVIMED